SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
https://www.hal.inserm.fr/inserm-03261177 Contributor : laboratoire CarMeNConnect in order to contact the contributor Submitted on : Tuesday, June 15, 2021 - 2:57:16 PM Last modification on : Monday, May 30, 2022 - 4:16:03 PM Long-term archiving on: : Thursday, September 16, 2021 - 6:50:52 PM
P. Sarafidis, C. J. Ferro, E. Morales, A. Ortiz, J. Malyszko, et al.. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, Oxford University Press, 2020, 35 (10), pp.1825. ⟨10.1093/ndt/gfz137⟩. ⟨inserm-03261177⟩